266 related articles for article (PubMed ID: 31278785)
21. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
22. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
23. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
24. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
25. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
27. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
[TBL] [Abstract][Full Text] [Related]
28. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
29. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
31. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
[TBL] [Abstract][Full Text] [Related]
32. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
[TBL] [Abstract][Full Text] [Related]
33. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
34. Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
Höcker B; Zencke S; Pape L; Krupka K; Köster L; Fichtner A; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Ozcakar ZB; Thiel F; Billing H; Pohl M; Fehrenbach H; Schnitzler P; Bruckner T; Ahlenstiel-Grunow T; Tönshoff B
Am J Transplant; 2016 Mar; 16(3):921-9. PubMed ID: 26613840
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
36. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
37. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
38. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
[TBL] [Abstract][Full Text] [Related]
40. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
